Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels

Sarah Zaheer, Kayla Meyer, Rebecca Easly, Omar Bayomy, Janet Leung, Andrew W Koefoed, Mahyar Heydarpour, Roy Freeman, Gail K Adler, Sarah Zaheer, Kayla Meyer, Rebecca Easly, Omar Bayomy, Janet Leung, Andrew W Koefoed, Mahyar Heydarpour, Roy Freeman, Gail K Adler

Abstract

Glucocorticoid use is the most common cause of secondary osteoporosis. Poor skeletal health related to glucocorticoid use is thought to involve inhibition of the Wnt/β-catenin signaling pathway, a key pathway in osteoblastogenesis. Sclerostin, a peptide produced primarily by osteocytes, is an antagonist of the Wnt/β-catenin signaling pathway, raising the possibility that sclerostin is involved in glucocorticoids' adverse effects on bone. The aim of this study was to determine whether an acute infusion of cosyntropin (i.e. ACTH(1-24)), which increases endogenous cortisol, increases serum sclerostin levels as compared to a placebo infusion. This study was performed using blood samples obtained from a previously published, double-blind, placebo-controlled, randomized, cross-over study among healthy men and women who received infusions of placebo or cosyntropin after being supine and fasted overnight (ClinicalTrials.gov NCT02339506). A total of 17 participants were analyzed. There was a strong correlation (R2 = 0.65, P < 0.0001) between the two baseline sclerostin measurements measured at the start of each visit, and men had a significantly higher average baseline sclerostin compared to women. As anticipated, cosyntropin significantly increased serum cortisol levels, whereas cortisol levels fell during placebo infusion, consistent with the diurnal variation in cortisol. There was no significant effect of cosyntropin as compared to placebo infusions on serum sclerostin over 6-24 h (P = 0.10). In conclusion, this randomized, placebo-controlled study was unable to detect a significant effect of a cosyntropin infusion on serum sclerostin levels in healthy men and women.

Keywords: ACTH; bone; cortisol; glucocorticoid; sclerostin.

Figures

Figure 1
Figure 1
Inpatient study design. Participants completed two study visits in random order with a 1–3 months wash-out period between the visits. At one study visit, they received two 2.5 h infusions of placebo (0.9% saline) and at the other visit they received two 2.5 h infusions of synthetic ACTH(1–24) (cosyntropin) 70 µg/h. Scl refers to the assessment of sclerostin levels. These were taken at baseline (before the morning infusion), immediately preceding the end of the second infusion, and the following day (24 h after baseline measures). Sclerostin levels were evaluated for both arms of the study and at both visits for each participant. Study design diagram is adapted from our previously published study (Leung et al. 2020).
Figure 2
Figure 2
Baseline sclerostin correlated by visit. Bivariate correlation between each individual’s baseline sclerostin values at the placebo visit and cosyntropin visit. Baseline sclerostin measurements were significantly correlated, P < 0.0001 (linear regression). There was a wide range of baseline sclerostin levels, however, for a given individual it remained consistent over the 1–3 months wash-out period. Open circles denote female participants and solid triangles denote male participants.
Figure 3
Figure 3
Effect of ACTH and placebo infusion on sclerostin concentrations. Serum sclerostin measurements were taken at baseline (pre-infusion), at the end of the afternoon infusion (approximately 6.5 h after the start of the morning infusion), and the following day (24 h after baseline measures). Placebo visit is represented by the white boxes and ACTH visit by the gray boxes. Whiskers extend to maximum and minimum value, the box represents the interquartile range, X denotes the mean, and the line inside the box shows the median. Data points outside the whiskers show the outliers. A mixed model analysis showed no effect of cosyntropin vs placebo over time (P = 0.10).
Figure 4
Figure 4
Sclerostin 24-h change from baseline in females (n  = 7) and males (n  = 10) after placebo or ACTH infusion. Twenty-four-hour change from baseline in serum sclerostin for the placebo visit is represented by the white boxes and ACTH visit by the gray boxes. Females are shown on the left and males on the right. Whiskers extend to maximum and minimum value, the box represents the interquartile range, X denotes the mean, and the line inside the box shows the median. Data points outside the whiskers show the outliers. P values were obtained using a Fisher’s exact test for men and women separately.

References

    1. Guañabens N, Gifre L, Peris P. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Current Osteoporosis Reports 20141290–97. (10.1007/s11914-014-0197-0)
    1. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nature Medicine 201319179–192. (10.1038/nm.3074)
    1. Rossini M, Gatti D, Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcified Tissue International 201393121–132. (10.1007/s00223-013-9749-z)
    1. Ramli FF, Chin KY. A review of the potential application of osteocyte-related biomarkers, fibroblast growth factor-23, sclerostin, and Dickkopf-1 in predicting osteoporosis and fractures. Diagnostics 202010145. (10.3390/diagnostics10030145)
    1. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. Journal of Bone and Mineral Research 2009241651–1661. (10.1359/jbmr.090411)
    1. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB Journal 2005191842–1844. (10.1096/fj.05-4221fje)
    1. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 200528019883–19887. (10.1074/jbc.M413274200)
    1. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton Ket al.Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 2003226267–6276. (10.1093/emboj/cdg599)
    1. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochemical and Biophysical Research Communications 2005329177–181. (10.1016/j.bbrc.2005.01.117)
    1. Compston J.Glucocorticoid-induced osteoporosis: an update. Endocrine 2018617–16. (10.1007/s12020-018-1588-2)
    1. Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects and systemic implications. Trends in Endocrinology and Metabolism 201425197–211. (10.1016/j.tem.2013.12.006)
    1. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 20041451835–1841. (10.1210/en.2003-0990)
    1. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 1998102274–282. (10.1172/JCI2799)
    1. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis and Rheumatism 2008581674–1686. (10.1002/art.23454)
    1. Beier EE, Sheu TJ, Resseguie EA, Takahata M, Awad HA, Cory-Slechta DA, Puzas JE. Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Research 20175 17013. (10.1038/boneres.2017.13)
    1. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis and Rheumatism 2011632385–2395. (10.1002/art.30385)
    1. Yao W, Dai W, Jiang L, Lay EY, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporosis International 201627283–294. (10.1007/s00198-015-3308-6)
    1. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong Jet al.Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research 200823860–869. (10.1359/jbmr.080216)
    1. Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin. Journal of Bone and Mineral Research 2016311791–1802. (10.1002/jbmr.2869)
    1. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. Journal of Clinical Endocrinology and Metabolism 201297E1953–E1957. (10.1210/jc.2012-2218)
    1. Athimulam S, Delivanis D, Thomas M, Young WF, Khosla S, Drake MT, Bancos I. The impact of mild autonomous cortisol secretion on bone turnover markers. Journal of Clinical Endocrinology and Metabolism 20201051469–1477. (10.1210/clinem/dgaa120)
    1. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporosis International 2013242191–2199. (10.1007/s00198-013-2268-y)
    1. Gifre L, Ruiz-Gaspà S, Monegal A, Nomdedeu B, Filella X, Guañabens N, Peris P. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 201357272–276. (10.1016/j.bone.2013.08.016)
    1. Brabnikova Maresova K, Pavelka K, Stepan JJ. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcified Tissue International 201392354–361. (10.1007/s00223-012-9684-4)
    1. Fassio A, Adami G, Giollo A, Viapiana O, Malavolta N, Saviola G, Bortolotti R, Idolazzi L, Bertoldo F, Rossini Met al.Acute effects of glucocorticoid treatment, TNFα or IL-6R blockade on bone turnover markers and Wnt inhibitors in early rheumatoid arthritis: a pilot study. Calcified Tissue International 2020106371–377. (10.1007/s00223-019-00649-3)
    1. Kawazoe M, Kaneko K, Shikano K, Kusunoki N, Nanki T, Kawai S. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. Clinical Rheumatology 2018372169–2178. (10.1007/s10067-017-3689-3)
    1. Fassio A, Adami G, Idolazzi L, Giollo A, Viapiana O, Vantaggiato E, Benini C, Rossini M, Dejaco C, Gatti D. Wnt inhibitors and bone turnover markers in patients with polymyalgia rheumatica and acute effects of glucocorticoid treatment. Frontiers in Medicine 20207 551. (10.3389/fmed.2020.00551)
    1. Jacobsson M, van Raalte DH, Heijboer AC, den Heijer M, de Jongh RT. Short-term glucocorticoid treatment reduces circulating sclerostin concentrations in healthy young men: a randomized, placebo-controlled, double-blind study. JBMR Plus 20204 e10341. (10.1002/jbm4.10341)
    1. Pickering ME, Simon M, Sornay-Rendu E, Chikh K, Carlier MC, Raby AL, Szulc P, Confavreux CB. Serum sclerostin increases after acute physical activity. Calcified Tissue International 2017101170–173. (10.1007/s00223-017-0272-5)
    1. Kouvelioti R, Kurgan N, Falk B, Ward WE, Josse AR, Klentrou P. Response of sclerostin and bone turnover markers to high intensity interval exercise in young women: does impact matter? BioMed Research International 201820184864952. (10.1155/2018/4864952)
    1. Diaz-Castro J, Mira-Rufino PJ, Moreno-Fernandez J, Chirosa I, Chirosa JL, Guisado R, Ochoa JJ. Ubiquinol supplementation modulates energy metabolism and bone turnover during high intensity exercise. Food and Function 2020117523–7531. (10.1039/d0fo01147a)
    1. Leung JH, Bayomy OF, Bonyhay I, Celli J, White J, Freeman R, Adler GK. ACTH infusion impairs baroreflex sensitivity-implications for cardiovascular hypoglycemia-associated autonomic failure. Journal of Clinical Endocrinology and Metabolism 20201052345–2352. (10.1210/clinem/dgaa221)
    1. Swanson C, Shea SA, Wolfe P, Markwardt S, Cain SW, Munch M, Czeisler CA, Orwoll ES, Buxton OM. 24-hour profile of serum sclerostin and its association with bone biomarkers in men. Osteoporosis International 2017283205–3213. (10.1007/s00198-017-4162-5)
    1. Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 2013981911–1915. (10.1210/jc.2012-4039)
    1. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. Journal of Clinical Endocrinology and Metabolism 201196E1848–E1851. (10.1210/jc.2011-1534)
    1. Dreyer T, Shah M, Doyle C, Greenslade K, Penney M, Creeke P, Kotian A, Ke HZ, Naidoo V, Holdsworth G. Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis. Journal of Orthopaedic Translation 202129134–142. (10.1016/j.jot.2021.05.005)
    1. Sebastian A, Loots GG. Transcriptional control of Sost in bone. Bone 20179676–84. (10.1016/j.bone.2016.10.009)
    1. Gould NR, Williams KM, Joca HC, Torre OM, Lyons JS, Leser JM, Srikanth MP, Hughes M, Khairallah RJ, Feldman RAet al.Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein. eLife 202110e64393. (10.7554/eLife.64393)
    1. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. Journal of Clinical Endocrinology and Metabolism 201297148–154. (10.1210/jc.2011-2152)
    1. Xu Y, Gao C, He J, Gu W, Yi C, Chen B, Wang Q, Tang F, Xu J, Yue Het al.Sclerostin and its associations with bone metabolism markers and sex hormones in healthy community-dwelling elderly individuals and adolescents. Frontiers in Cell and Developmental Biology 20208 57. (10.3389/fcell.2020.00057)
    1. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. Journal of Bone and Mineral Research 201126373–379. (10.1002/jbmr.217)

Source: PubMed

3
Subscribe